Meeting
2015 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).
Authors
Steven Attia
Mayo Clinic, Jacksonville, FL
Steven Attia , Richard F. Riedel , Steven Ian Robinson , Robert Martin Conry , Kamalesh Kumar Sankhala , Ben K. Seon , Delia Alvarez , Bonne J. Adams , Charles P. Theuer , Robert G. Maki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01975519
Citation
J Clin Oncol 33, 2015 (suppl; abstr 10514)
DOI
10.1200/jco.2015.33.15_suppl.10514
Abstract #
10514
Poster Bd #
158
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).
First Author: Steven Attia
Poster
2013 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).
First Author: Ellis Glenn Levine
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2022 ASCO Annual Meeting
BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.
First Author: Jennifer L. Spratlin